Follitrope Dosage/Direction for Use

Treatment with Follitropin alfa (Follitrope) should be initiated under the supervision of a physician experienced in the treatment of fertility problems.
Follitropin alfa (Follitrope) is intended for subcutaneous or intramuscular administration.
Women undergoing ovarian stimulation for multiple follicular development prior to in vitro fertilization or other assisted reproductive technologies: Various stimulation protocols are applied in order to suppress the endogenous LH surge and to control tonic levels of LH. A commonly used regimen for hyperovulation involves the administration of 150-300 IU of Follitropin alfa (Follitrope) daily, commencing on days 2 to 5 of the cycle. Treatment is continued until adequate follicular development has been achieved (as assessed by monitoring of serum oestrogen levels and/or ultrasound examination), with the dose adjusted according to the patient's response, to usually not higher than 450 IU daily. In general, adequate follicular development was achieved on average by the tenth day of treatment. A single injection of up to 10,000 IU hCG is administered 48 hours after the last Follitropin alfa (Follitrope) injection to induce final follicular maturation.
Women with anovulation (including PCOD): The object of Follitropin alfa (Follitrope) therapy is to develop a single mature Graafian follicle from which the ovum will be liberated after the administration of hCG.
Follitropin alfa (Follitrope) may be given as a course of daily injections. In menstruating patients treatment should commence within the first 7 days of the menstrual cycle.
Treatment should be tailored to the individual patient's response as assessed by measuring follicle size by ultrasound and/or oestrogen secretion. A commonly used regimen commences at 75-150 IU FSH daily and is increased by 75 IU at 7 or preferably 14 day intervals if necessary, to obtain an adequate, but not excessive, response. The maximal daily dose is usually not higher than 225 IU FSH. If a patient fails to respond adequately after 4 weeks of treatment, that cycle should be abandoned and the patient should recommence treatment at a higher starting dose than in the abandoned cycle.
When an optimal response is obtained, a single injection of 5,000 IU or up to 10,000 IU hCG should be administered 24-48 hours after the last Follitropin alfa (Follitrope) injection. The patient is recommended to have coitus on the day of, and the day following, hCG administration. Alternatively intrauterine insemination (IUI) may be performed.
If an excessive response is obtained, treatment should be stopped and hCG withheld. The treatment should recommence in the next cycle at a dosage lower than that of the previous cycle.